NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Effect of Ectoin® Inhalation Solution on Subjects With Mild Bronchial Asthma
Effect of Ectoin® Inhalation Solution on Subjects With Mild Bronchial Asthma

NCT01478152

CompletedNA

Sponsor: Bitop AG

Conditions: Asthma

Interventions: Drug-like Medical Device: Ectoin Inhalation Solution

Countries: Germany

In this single center, dose finding, safety study the effect of inhaled Ectoin® inhalation solution will be investigated in subjects with mild bronchial asthma. This dose-finding study will estimate the minimum effective dose and will assess the safe dosage, in terms of the quantity given to patients. The results will be compared to baseline measurements. The results regarding Sputum measurements will be compared to measurements after placebo administration.

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Adults (18 - 65 years)
* FEV1 ≥ 80% of predicted for patient's normal value pre bronchodilator (according to European Coal and Steel Community reference values)
* Positive Methacholine challenge test (PD20 ≤ 0.5 mg)
* A general practitioner or consultant diagnosed mild bronchial asthma
* Non or ex smoker (for more than 6 months, pack years (PY) ≤ 5)

Exclusion Criteria:

* Pregnant or lactating females
* Participation in another clinical study in the previous month
* Severe concomitant disease which may have an impact on the study participation
* Hypersensibility against Ectoin®
* Patients who have had treatment with live attenuated vaccinations within 14 days prior to screening visit (Inactivated influenza vaccination is acceptable, provided it is not administered within 7 days prior to screening visit).
* Other respiratory diseases (e.g. Chronic obstructive pulmonary disease (COPD), cystic fibrosis, alpha-1-Antitrypsin deficiency, sarcoidosis, bronchiectasis, allergic alveolitis, tuberculosis, etc.)
* Upper and lower airway respiratory infection within 4 weeks prior to study start
Locations (1)
  • Gauting, Bavaria, Germany